Skip to content

Bevacizumab total-serum exposure

Intravenous bevacizumab distributes between serum and a peripheral compartment and undergoes linear elimination. The independent PK-only parameter set supports conditional total-drug concentration and exposure exploration.

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients ↗
Exploration notes · What are you exploring?

Notes stay on this browser.

Run settings

Run location

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

5 mg/kg every 2 weeks · 90 then 60 minutes

Independent Table 3 PK-only final fit. Typical fixed effects; no original patients, variability or observation noise. First infusion 90 min, subsequent 60 min; conditional Methods schedule, not known patient histories. Figure 3 is generated by the TMDD model and is not a PK-only validation target.

0–126 day

Study

5 mg/kg every 2 weeks · 90 then 60 minutes

Independent Table 3 PK-only final fit. Typical fixed effects; no original patients, variability or observation noise. First infusion 90 min, subsequent 60 min; conditional Methods schedule, not known patient histories. Figure 3 is generated by the TMDD model and is not a PK-only validation target.

Readouts

Total serum bevacizumab· mg/L
Total drug in the central compartment; free and bound drug are not separated.
Cumulative serum exposure· mg*day/L
Integral of total central concentration from the selected simulation start.

Study purpose

  • How do linear distribution and clearance shape total serum exposure under this fixed infusion history?

Interpretation limits

  • Conditional deterministic total-serum bevacizumab PK only. No VEGF binding, free-drug separation, efficacy, safety, individual patient inference or clinical dosing recommendation.
  • This is the independently fitted PK-only Table 3 model, not the Table 3 TMDD fit or the source Figure 3 binding-model curves.
  • The 19-patient population fit, random effects, 24% proportional residual error, original dosing histories and supplemental goodness-of-fit panels are not reproduced.
  • Q and peripheral volume have source relative standard errors of 146% and 50%. Exploratory 0.5–1.5× parameter ranges are not confidence intervals.
  • Bodyweight jointly scales CL and Q with exponent 0.75 and volumes with exponent 1.0. Weight is fixed by each starting configuration. Disposition controls do not change administered doses.
  • Visible histories use first 90-minute then 60- or 30-minute infusions. The original 85-minute median-duration approximations remain retained diagnostics, not known patient histories.
  • Both compartments represent total drug; free and bound drug are not separated.
  • Changing the simulation start resets the supplied initial states and does not reconstruct earlier drug amounts. An overlapping infusion delivers only its remaining portion. AUC integrates from that selected start.
  • No complete source figure panel or original estimation has been reproduced. Human scientific review remains pending.
Loading starting example…

Edit inputs

PK disposition

Independent Table 3 PK-only estimate at 70 kg. Exploratory 0.5–1.5× range; not a confidence interval. Bodyweight and administered doses remain fixed by the selected configuration.

L/day
0.17 → —

Independent Table 3 PK-only estimate at 70 kg. Exploratory 0.5–1.5× range; not a confidence interval. Bodyweight and administered doses remain fixed by the selected configuration.

L
3.14 → —

Independent Table 3 PK-only estimate at 70 kg. Exploratory 0.5–1.5× range; not a confidence interval. Bodyweight and administered doses remain fixed by the selected configuration.

L/day
0.36 → —

Independent Table 3 PK-only estimate at 70 kg. Exploratory 0.5–1.5× range; not a confidence interval. Bodyweight and administered doses remain fixed by the selected configuration.

L
2.63 → —
Simulation time
day
day
126 → 168

Time between reported samples.

day

1 change · Variation 1

Continue in the background and keep the result.

Biology

Intravenous bevacizumab distributes between serum and a peripheral compartment and undergoes linear elimination. The independent PK-only parameter set supports conditional total-drug concentration and exposure exploration.

Intravenous bevacizumab distributes between serum and a peripheral compartment and undergoes linear elimination. The independent PK-only parameter set supports conditional total-drug concentration and exposure exploration.
States & equation dependencies
What are the modeled states and equation-linked processes?Representative technical topology with 4 selected states: Total central-compartment drug amount, Peripheral total bevacizumab amount, Total bevacizumab AUC, Elapsed time. Displayed equation-linked dependencies: between Peripheral total bevacizumab amount and Total central-compartment drug amount; from Total central-compartment drug amount to Total bevacizumab AUC. Displayed model or scenario entry points: Administered input enters Total central-compartment drug amount. There are no separately labeled equation controls.TECHNICAL TOPOLOGYWhat are the modeled states and equation-linked processes?Selected equation-linked states · model time unit: dayAdministered inputTotal central-compartmentdrug amountmgPeripheral total bevacizumabamountmgTotal bevacizumab AUCmg*day/LElapsed timeday
Teal arrows show relationships between modeled states and do not always represent material transfer. Peach arrows mark administered or scenario-defined entry points.

Assumptions & evidence

Assumptions & limitations

  • Conditional deterministic total-serum bevacizumab PK only. No VEGF binding, free-drug separation, efficacy, safety, individual patient inference or clinical dosing recommendation.
  • This is the independently fitted PK-only Table 3 model, not the Table 3 TMDD fit or the source Figure 3 binding-model curves.
  • The 19-patient population fit, random effects, 24% proportional residual error, original dosing histories and supplemental goodness-of-fit panels are not reproduced.
  • Q and peripheral volume have source relative standard errors of 146% and 50%. Exploratory 0.5–1.5× parameter ranges are not confidence intervals.
  • Bodyweight jointly scales CL and Q with exponent 0.75 and volumes with exponent 1.0. Weight is fixed by each starting configuration. Disposition controls do not change administered doses.
  • Visible histories use first 90-minute then 60- or 30-minute infusions. The original 85-minute median-duration approximations remain retained diagnostics, not known patient histories.
  • Both compartments represent total drug; free and bound drug are not separated.
  • Changing the simulation start resets the supplied initial states and does not reconstruct earlier drug amounts. An overlapping infusion delivers only its remaining portion. AUC integrates from that selected start.
  • No complete source figure panel or original estimation has been reproduced. Human scientific review remains pending.

Parameter origins

  • Released executable model definition; exact publication locator not reported

Validation & references

One or more implementation checks are available; this is not a claim of full model reproduction.

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients ↗

Available reference curves can be added to the plot when their scenario, readout, time and units match.

Model details

8 parameters · 4 states · 4 equations · 4 derived outputs

Classification & API access
Therapeutic
Bevacizumab
Modality
Monoclonal antibody
Target
VEGFA, VEGF165
Disease / scope
adult stage IV colorectal cancer
ParameterDefaultUnitDescription
Systemic clearanceCL_L_day0.17L/dayIndependent Table 3 PK-only estimate at 70 kg. Exploratory 0.5–1.5× range; not a confidence interval. Bodyweight and administered doses remain fixed by the selected configuration.
Intercompartmental clearanceQ_L_day0.36L/dayIndependent Table 3 PK-only estimate at 70 kg. Exploratory 0.5–1.5× range; not a confidence interval. Bodyweight and administered doses remain fixed by the selected configuration.
Central distribution volumeV1_L3.14LIndependent Table 3 PK-only estimate at 70 kg. Exploratory 0.5–1.5× range; not a confidence interval. Bodyweight and administered doses remain fixed by the selected configuration.
Peripheral distribution volumeV2_L2.63LIndependent Table 3 PK-only estimate at 70 kg. Exploratory 0.5–1.5× range; not a confidence interval. Bodyweight and administered doses remain fixed by the selected configuration.
Body weightbody_weight_kg70kgBody weight used for body-size scaling in the model.
Reference body weightreference_weight_kg70kgReference body weight coefficient used by the released system of model equations.
Fixed allometric exponent on clearancetheta_cl_weight0.75dimensionlessFixed allometric exponent on clearance governing removal of modeled material from the relevant compartment.
Fixed allometric exponent on volumestheta_v_weight1dimensionlessFixed allometric exponent on volumes coefficient used by the released system of model equations.

Related models

Bevacizumab PK and VEGF165 target binding

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics